Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IRB Handovers Harmonized In Eight-Fold Path Outlined By FDA, OHRP

This article was originally published in The Pink Sheet Daily

Executive Summary

Joint draft guidance on institutional review board switching for industry- and federal government-sponsored clinical trials advances the agencies’ goal creating umbrella coverage in human subject protection.


Related Content

Central IRBs, Data Security Standards Feature In Overhaul Of "Common Rule"
IRB Quality Concerns Take Center Stage After FDA Clamps Down On Coast
Two Draft Guidances Address Trial-Related Adverse Events





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts